Preoperative 4-week supplementation with omega-3 polyunsaturated fatty acids reduces liver volume and facilitates bariatric surgery in morbidly obese patients

Obesity Surgery

Volumn 23, Issue 11, 2013, Pages 1761-1765

  Iannelli, Antonio ^a,b   Martini, Francesco ^a,b   Schneck, Anne Sophie ^a,b   Ghavami, Bijan ^a   Baudin, Guillaume ^a,b   Anty, Rodolphe ^a,b   Gugenheim, Jean ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Bariatric surgery; Laparoscopic Roux en Y gastric bypass; Liver volume; Morbid obesity; Non alcoholic fatty liver disease; Omega 3 polyunsaturated fatty acids

Indexed keywords

EPACAPS; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BARIATRIC SURGERY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; HEPATOMEGALY; HUMAN; LAPAROSCOPIC SURGERY; LIVER WEIGHT; MALE; MORBID OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FATTY LIVER; FEMALE; FRANCE; GASTRIC BYPASS; HUMANS; LAPAROSCOPY; LIVER; MALE; MIDDLE AGED; OBESITY, MORBID; ORGAN SIZE; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84885483974     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0942-y     Document Type: Article

References (52)

1. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol. 2009;7(2):135-40.
2. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-25.
3. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46(2):582-9.
4. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-21.
5. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73.
6. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042-7.
7. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5-S10.
8. Gaba RC, Knuttinen MG, Brodsky TR, et al. Hepatic steatosis: correlations of body mass index, CT fat measurements, and liver density with biopsy results. Diagn Interv Radiol. 2012;18(3):282-7.
9. Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol. 2008;23(6):900-7.
10. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49(1):306-17.
11. Beymer C, Kowdley KV, Larson A, et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138(11):1240-4.
12. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22(3):222-6.
13. Schwartz ML, Drew RL, Chazin-Caldie M. Factors determining conversion from laparoscopic to open Roux-en-Y gastric bypass. Obes Surg. 2004;14(9):1193-7.
14. Fris RJ. Preoperative low energy diet diminishes liver size. Obes Surg. 2004;14(9):1165-70.
15. Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol. 2006;40 Suppl 1:S44-50.
16. Benjaminov OBN, Gindy L, Spivak H, et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc. 2007;21(8):1423-7.
17. Edholm DKJ, Haenni A, Karlsson FA, et al. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese. Obes Surg. 2011;21(3):345-50.
18. Frutos MDMM, Luján J, Hernández Q, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg. 2007;17(2):150-4.
19. Lewis MCPM, Slavotinek JP, Kow L, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16(6):697-701.
20. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304-11.
21. Abuissa H, O'Keefe Jr JH, Harris W, et al. Autonomic function, omega-3, and cardiovascular risk. Chest. 2005;127(4):1088-91.
22. O'Keefe Jr JH, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97(8):1127-30.
23. Demarin V, Lisak M, Morovic S. Mediterranean diet in healthy lifestyle and prevention of stroke. Acta Clin Croat. 2011;50(1):67-77.
24. Di Minno MN, Tremoli E, Tufano A, et al. Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb Haemost. 2010;104(4):664-80.
25. Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes - 2006: a position statement of the American Diabetes Association. Diabetes Care. 2006;29(9):2140-57.
26. Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl 1:S61-78.
27. De Caterina R, Madonna R, Bertolotto A, et al. n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care. 2007;30(4):1012-26.
28. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-57.
29. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-2.
30. Chen RGQ, Zhu WJ, Xie Q, et al. Therapeutic efficacy of (omega)-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease. World Chin J Digestol. 2008;16:2002-6.
31. De Assis AM, Rech A, Longoni A, et al. Ω3-Polyunsaturated fatty acids prevent lipoperoxidation, modulate antioxidant enzymes, and reduce lipid content but do not alter glycogen metabolism in the livers of diabetic rats fed on a high fat thermolyzed diet. Mol Cell Biochem. 2012;361(1-2):151-60.
32. Parker HMJN, Burdon CA, Cohn JS, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56(4):944-51.
33. Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr. 2010;61(8):792-802.
34. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):194-9.
35. Tarantino GSG, Conca P, Arena A. Nonalcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol. 2007;22:293-303.
36. Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14(41):6395-400.
37. Shapiro H, Tehilla M, Attal-Singer J, et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr. 2011;30(1):6-19.
38. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956-61.
39. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65(6 Pt 2):S57-63.
40. Buckley JDHP. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev. 2009;10(6):648-59.
41. Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477-84.
42. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2):235-40.
43. Paredes AHTD, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis. 2012;16(2):397-419.
44. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647-54.
45. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16(10):1278-86.
46. St George A, Bauman A, Johnston A, et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24(3):399-407.
47. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242(4):610-7. discussion 618-20.
48. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80-6.
49. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2012;51(1):121-9.
50. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-31.
51. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42(4):413-8.
52. Li Y, Chen D. The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease. J Hepatol. 2012;57(2):468-9. author reply 469-70.